Hemab Therapeutics Holdings, Inc.

The Company believes its current cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements into 2029.

SEC original ↗Hemab Therapeutics Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026

If we engage in future acquisitions, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company has financed its operations primarily through private placements of convertible preference shares and issuance of convertible debt and, most recently, from the sale of common stock in its IPO in May 2026.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company believes that its existing cash, cash equivalents, and marketable securities will enable it to fund its operating expenses and capital expenditure requirements for at least one year from the date of the issuance of these unaudited condensed consolidated financial statements.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Until such a time when the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company s investment portfolio is primarily comprised of short term debt securities issued by the U.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

In Europe, the European Medicines Agency (EMA) has granted sutacimig Orphan Medicinal Product designation for the treatment of GT and access to the Priority Medicines (PRIME) scheme.

SEC original ↗Hemab Therapeutics Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026

Food and Drug Administration has granted Fast Track Designation, Orphan Drug Designation, and Breakthrough Therapy Designation to sutacimig for the treatment of GT, and the UK Medicines and Healthcare products Regulatory Agency has awarded sutacimig designation under the Innovative Licensing and Access Pathway (ILAP); it has been designated as an orphan medicinal product in the European Union for the treatment of GT, and the European Medicines Agency (EMA) has granted sutacimig access to the Priority Medicines (PRIME) scheme.

SEC original ↗Hemab Therapeutics Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026

Despite its prevalence, current treatment options for VWD primarily focus on managing symptoms rather than addressing the underlying biology of the disease.

SEC original ↗Hemab Therapeutics Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026

All statements, other than statements of historical facts, contained in this press release, including statements regarding Hemab s strategy, future operations, prospects and plans, objectives of management, the anticipated timelines for reporting data from Hemab s clinical trials, the anticipated timelines for initiating a Phase 3 clinical trial of sutacimig and further development of HMB-002 and HMB-003, the clinical potential of sutacimig, HMB-002 and HMB-003, Hemab s plans to expand its pipeline, and the sufficiency of Hemab s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

SEC original ↗Hemab Therapeutics Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026

All statements, other than statements of historical fact, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties.

SEC original ↗Hemab Therapeutics Holdings, Inc. — Earnings release (8-K exhibit)EX-99Aug 11, 2026

Legal Proceedings 43 Item 1A.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties that could have an impact on us, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

If we are unable to remedy our material weaknesses, or if we fail to establish and maintain an effective system of internal control over financial reporting, we may be unable to produce timely and accurate financial statements or prevent fraud, which could adversely impact our business and our stock price.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Risks and Uncertainties The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026

Genmab may terminate the Genmab Agreement if the Company or its affiliates or sublicensees challenge any of the platform technology patent rights licensed under the Genmab Agreement.

SEC original ↗Hemab Therapeutics Holdings, Inc. — 10-Q Quarterly report10-QAug 11, 2026